EPSS Directive 1149/2026 Ethiopia: New Law Unifies Pharma Supply Chain

• The Ethiopian Pharmaceuticals Supply Service (EPSS) has repealed three major directives governing pharmaceutical operations.
• These directives previously covered warehousing, distribution, and procurement forecasting within the country.
• A new unified framework, the Ethiopian Pharmaceuticals Supply Service Pharmaceutical Demand and Inventory, Warehouse and Distribution Management Directive No. 1149/2026, replaces the repealed laws.
• The new EPSS Directive 1149/2026 Ethiopia aims to align supply planning and inventory management with modern operating structures and digital systems.
• The directive establishes a single set of rules for the entire pharmaceutical supply chain, from storage to distribution and forecasting.

For legal professionals and compliance officers tasked with advising pharmaceutical companies, a comprehensive understanding and deep dive into EPSS Directive 1149/2026 Ethiopia is not merely beneficial but absolutely imperative.

The Ethiopian Pharmaceuticals Supply Service (EPSS) has recently initiated a significant transformation within the nation's pharmaceutical regulatory environment. This crucial development involves the complete annulment of three distinct directives that previously governed key operational areas: warehousing, the distribution of medical supplies, and the methodology for forecasting procurement needs. The primary objective behind this action is to integrate these separate regulations into a singular, cohesive framework, thereby ushering in a new era for pharmaceutical supply chain management across Ethiopia.

This comprehensive regulatory update introduces the Ethiopian Pharmaceuticals Supply Service Pharmaceutical Demand and Inventory, Warehouse and Distribution Management Directive No. 1149/2026. The new directive is specifically engineered to streamline operational processes and foster enhanced efficiency throughout the entire pharmaceutical supply chain. Its implementation underscores a strategic commitment by the EPSS to modernize its operational approach, ensuring that its supply planning and inventory management practices are fully aligned with contemporary operating structures and advanced digital systems. This move is expected to create a more harmonized and effective system for managing vital medical resources.

The recently enacted EPSS Directive 1149/2026 Ethiopia establishes a comprehensive and unified set of guidelines for managing pharmaceutical products, from their initial entry into the supply chain to their final distribution points. By superseding the previously fragmented regulatory landscape, this directive aims to cultivate a more integrated, transparent, and accountable system. The extensive scope of this Ethiopia pharmaceutical supply chain law encompasses all critical facets of inventory control, detailed storage protocols, and the efficient movement of essential medicines and related supplies throughout the country.

More specifically, the directive meticulously addresses the complexities of warehousing, instituting new, rigorous standards for storage conditions, environmental controls, and precise inventory tracking mechanisms. It also fundamentally redefines the operational parameters for distribution, with a clear mandate to ensure that pharmaceutical products reach their intended destinations both efficiently and securely, maintaining their integrity. Furthermore, the EPSS inventory rules articulated within this directive provide a revised and optimized methodology for procurement forecasting, designed to achieve optimal stock levels and significantly mitigate instances of shortages or overstocking within the national supply network. This strategic consolidation reflects a profound commitment to bolstering the overall resilience, responsiveness, and reliability of the nation's pharmaceutical supply infrastructure.

The introduction of the Ethiopian Pharmaceuticals Supply Service Pharmaceutical Demand and Inventory, Warehouse and Distribution Management Directive No. 1149/2026 carries substantial and far-reaching implications for all entities actively engaged in the pharmaceutical sector within Ethiopia. Organizations operating in the country are now mandated to undertake a meticulous review of their existing operational practices to ensure complete and unwavering adherence to this new, unified regulatory framework. This critical assessment must encompass a thorough examination of their warehousing procedures, the efficiency and compliance of their distribution networks, and the accuracy and methodology of their procurement forecasting models, all to align precisely with the updated Ethiopia drug distribution regulations.

For legal professionals and compliance officers tasked with advising pharmaceutical companies, a comprehensive understanding and deep dive into EPSS Directive 1149/2026 Ethiopia is not merely beneficial but absolutely imperative. It is their responsibility to provide expert guidance to clients, assisting them in the crucial process of updating internal policies and refining operational procedures to accurately reflect these significant regulatory changes. Ensuring robust compliance with this new directive is paramount, not only for avoiding potential legal penalties and operational disruptions but also for actively contributing to the establishment of a more efficient, transparent, and reliable national pharmaceutical supply chain, which will ultimately enhance public health outcomes across the entire nation.

Lawyers and compliance officers advising pharmaceutical companies in Ethiopia must review Directive No. 1149/2026 to ensure client operations comply with the new unified framework for warehousing, distribution, and procurement forecasting, updating internal policies and procedures accordingly.

Source: Original reporting via industry sources